Rapport Therapeutics assigned Buy rating at Goldman Sachs

Goldman Sachs analyst Salveen Richter assigned Rapport Therapeutics (RAPP) with a Buy rating and $51 price target from its Early-Stage Biotech designation. RAP-219’s Phase 2 epilepsy data showed a 71% reduction in long episodes, the primary endpoint, with 24% achieving seizure freedom for the eight-week treatment period, the analyst tells investors in a research note. Goldman now views RAP-219 as well-positioned into the Phase 3 study given the Phase 2 “de-risking.”